Crohn's Disease Activity and Concomitant Immunosuppressants Affect the Risk of Serious and Opportunistic Infections in Patients Treated With Adalimumab.
Fiche publication
Date publication
décembre 2016
Journal
The American journal of gastroenterology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr PEYRIN-BIROULET Laurent
Tous les auteurs :
Osterman MT, Sandborn WJ, Colombel JF, Peyrin-Biroulet L, Robinson AM, Zhou Q, Lewis JD
Lien Pubmed
Résumé
Anti-tumor necrosis factor (TNF) drugs are commonly used to treat moderate-to-severe Crohn's disease (CD). Both the activity of CD and the concomitant immunosuppressants (corticosteroids and immunomodulators) used with anti-TNF drugs could increase the risk of infection. We determined the relative risk of serious and opportunistic infections associated with increasing disease activity and concomitant immunomodulators and corticosteroids in patients with CD treated with adalimumab.
Mots clés
Adalimumab, therapeutic use, Adrenal Cortex Hormones, therapeutic use, Adult, Anti-Inflammatory Agents, therapeutic use, Crohn Disease, drug therapy, Drug Therapy, Combination, Female, Herpes Zoster, epidemiology, Humans, Immunologic Factors, therapeutic use, Immunosuppressive Agents, therapeutic use, Male, Methotrexate, therapeutic use, Middle Aged, Multivariate Analysis, Opportunistic Infections, epidemiology, Proportional Hazards Models, Risk Factors, Severity of Illness Index, Young Adult
Référence
Am. J. Gastroenterol.. 2016 12;111(12):1806-1815